Overall, the DDDs for both drugs showed an increasing trend during the study period, with only a relatively significant decrease in the fourth quarter of 2022 for both drugs.
← all excerpts
Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation.
1
—
—